Melanotan II Research: Melanocortin Biology, Early Human Studies, and Evidence Limits

The short version

Melanotan II, often abbreviated MT-II or MT-2, is a synthetic cyclic peptide derived from alpha-melanocyte-stimulating hormone research. It activates several melanocortin receptor subtypes rather than one single target. That receptor breadth helps explain why the literature spans pigmentation, energy balance, and sexual-behavior research, but it also makes simple one-effect descriptions misleading.

The human evidence is exceptionally small. An initial study involved three healthy men, followed by two crossover studies of ten men each. These experiments reported pigmentation or erectile-response signals alongside nausea and other adverse effects, but they were not large or long enough to establish clinical efficacy, uncommon harms, long-term safety, or an approved use.

Melanotan II is not an FDA-approved drug. It is also not the same compound as afamelanotide, the active ingredient in the FDA-approved product Scenesse, or bremelanotide, the active ingredient in Vyleesi. Published biology does not authenticate any current supplier material, and an HPLC purity percentage cannot establish complete identity or suitability by itself.

Identity: a cyclic melanocortin analog

The early clinical publication describes Melanotan II as the cyclic heptapeptide Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, with a lactam bridge between the aspartic-acid and lysine side chains. The represented structure therefore includes more than an amino-acid list: an acetylated N-terminus, norleucine, D-phenylalanine, a defined ring closure, and a C-terminal amide all contribute to molecular identity.

FDA's substance-registration record identifies Melanotan II under UNII UPF5CJ93X7 and lists the molecular formula C50H69N15O9. FDA also explains that a UNII is an identifier for a substance and does not imply regulatory review or approval.

Catalog spellings such as Melanotan II, Melanotan 2, MT-II, and MT-2 can refer to the intended compound, but a name alone cannot establish the actual contents of a sample. A defensible record connects the complete represented structure, expected mass, salt or counterion form, lot, sample, laboratory, method, and observed results.

Melanotan II, Melanotan I, and bremelanotide are not interchangeable

The shared melanocortin lineage creates persistent naming confusion. Melanotan I is commonly associated with afamelanotide, a linear alpha-MSH analog. Scenesse is a specific afamelanotide implant approved by FDA for increasing pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. That product-specific approval does not attach to Melanotan II.

Bremelanotide, also called PT-141, was developed from the Melanotan II lineage but is a different molecule. Vyleesi is a specific FDA-approved bremelanotide drug product. Evidence and labeling for Vyleesi cannot be transferred to MT-II or to a research-market vial bearing a related name.

These distinctions are chemical, pharmacological, and regulatory—not merely branding differences. When a paper, registry, supplier page, or laboratory report uses a melanotan name, the exact sequence, cyclization, terminal chemistry, and product identity should be resolved before evidence is compared.

Receptor pharmacology: one peptide, several melanocortin receptors

Melanocortin receptors are a family of G-protein-coupled receptors with different tissue distributions and physiological roles. Structure-activity research using Melanotan II and related analogs helped map ligand interactions at receptors including MC3R and MC4R. MT-II is generally treated as a nonselective agonist across several melanocortin receptor subtypes rather than as a molecule restricted to one receptor.

This matters because receptor activation is not a clinical outcome. A ligand can activate a receptor in a defined cell system while its whole-organism effects depend on exposure, receptor distribution, signaling bias, metabolism, model conditions, and competing pathways.

Mechanistic language should therefore remain bounded. Receptor experiments can support a claim that MT-II engages melanocortin signaling under the tested conditions; they cannot by themselves establish tanning efficacy, weight change, sexual effects, therapeutic value, or safety in humans.

Pigmentation biology and what it does not prove

MC1R signaling in melanocytes is central to eumelanin production, which provides a plausible biological route for pigmentation findings. The three-participant phase I report observed increased pigmentation in two volunteers, making pigmentation one of the few effects reported directly in an early human MT-II experiment.

That observation is not an adequate efficacy or safety database. Two responding participants cannot establish response frequency across skin types, durability, dose-response behavior, interactions with ultraviolet exposure, or long-term dermatologic risk. It also cannot support claims about a supplier's material, because the study test article and a current catalog product are not automatically equivalent.

Pigmentation is also not proof of protection from ultraviolet injury. Color change, DNA damage, erythema, photoaging, and cancer risk are different endpoints and require different evidence.

Animal evidence: MC4R helped explain energy-balance effects in mice

A mouse study compared responses to Melanotan II in ordinary animals and animals lacking the melanocortin-4 receptor. MT-II reduced food intake and increased metabolic rate in the ordinary mice, while those responses were absent in the MC4R-knockout mice. The result supported an important role for MC4R in those experimental effects.

Knockout designs are useful because loss of a response can test whether a receptor is necessary in a particular model. They do not show that the same intervention produces a safe, durable, or beneficial outcome in people. Developmental changes in knockout animals, species differences, laboratory conditions, and the selected endpoints all constrain translation.

The study is best read as mechanistic evidence about a mouse energy-balance pathway—not as clinical weight-management evidence and not as a recommendation for use.

Animal sexual-behavior findings were model- and endpoint-specific

In ovariectomized, hormone-primed female rats, investigators reported that Melanotan II enhanced selected proceptive behaviors under certain hormonal conditions. Not every measure of sexual receptivity changed in the same way, and the experimental preparation was deliberately constructed to isolate particular signaling questions.

These findings can help researchers study central melanocortin pathways. They do not establish a human clinical effect, apply across sexes or hormonal states, or substitute for adequately controlled human trials. Compressing the result into a broad claim that MT-II improves sexual function removes the model conditions and outcome distinctions that make the study interpretable.

The first human report included only three participants

The 1996 phase I pilot involved three healthy male volunteers. The publication reported pigmentation in two participants and spontaneous erections in all three. Nausea, fatigue, and sleepiness were among the reported adverse effects.

A three-person experiment can identify observations worth studying, but it cannot estimate how often an effect or adverse event occurs in a broader population. There was no statistical power for clinical efficacy, no meaningful characterization of uncommon harms, and no basis for extrapolating to women, people with medical conditions, or long-term exposure.

The correct evidence label is an early human pharmacology signal. It is not a therapeutic trial, an approval, or a validation of any current supplier material.

Two ten-participant crossover studies examined erectile responses

A double-blind, placebo-controlled crossover study enrolled ten men with psychogenic erectile dysfunction. The publication reported erections in eight of ten participants after MT-II and recorded nausea, stretching, yawning, and decreased appetite among observed effects.

A second double-blind, placebo-controlled crossover study involved ten men with erectile dysfunction and organic risk factors. Investigators reported objective rigidity and sexual-desire signals, while nausea and stretching or yawning also occurred; severe nausea was reported during some study exposures.

Crossover designs let participants serve as their own controls, which can be efficient in small early studies. They do not overcome the limitations of ten-person samples, short observation, selected male populations, multiple endpoints, or an inadequate safety database. These reports are early signals, not confirmation of a favorable benefit-risk profile.

What the human evidence does not establish

The published human evidence identified here totals only 23 participants across three small, older experiments, with overlap in the kinds of short-term pharmacologic observations being studied. None was a large, modern confirmatory trial designed to establish an approved indication.

The record does not establish long-term safety, uncommon adverse-event rates, effects across diverse populations, comparative effectiveness, durable outcomes, or a clinically appropriate benefit-risk balance. It also does not show that the material used in those experiments matches a product sold online today.

FDA approval of other melanocortin products cannot fill those gaps. Afamelanotide and bremelanotide have their own structures, finished products, indications, manufacturing controls, and evidence packages.

• Three exceptionally small human studies
• No large confirmatory MT-II efficacy program identified
• Short-term observations rather than long-term outcomes
• Adverse effects occurred even in the small studies
• No study authenticates a current research-supplier lot

Safety signals and case reports require careful interpretation

FDA's current safety-risk page for certain bulk substances says compounded Melanotan II may pose immunogenicity risk for some routes because of aggregation or peptide-related impurities. The agency also notes published case reports involving serious events such as melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.

A case report can identify a possible signal, document a clinical sequence, and motivate investigation. It generally cannot by itself establish incidence, quantify risk, prove causality, exclude contamination or co-exposures, or determine whether the named product contained the represented molecule.

The responsible conclusion is neither that every reported event was caused by MT-II nor that the reports can be ignored. They add uncertainty to an already limited human safety record and underscore why unverified online materials cannot be treated as characterized clinical products.

FDA status: no approved Melanotan II drug product

FDA has not approved a Melanotan II drug product. A 2007 warning letter addressed unlawful marketing of an unapproved injectable tanning product, and the agency's current safety-risk materials continue to discuss Melanotan II as an unapproved substance rather than an approved therapy.

The compounding-list record also needs current context. FDA's April 22, 2026 Category 2 update says the Melanotan II nomination was withdrawn, so the substance was removed from Category 2. FDA stated that it intended to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. Removal after a withdrawn nomination is not approval, a positive safety finding, or authorization to market a finished product.

Regulatory statements should remain product- and date-specific. A UNII, a withdrawn nomination, a planned advisory-committee discussion, a research-use label, or a supplier's disclaimer does not establish FDA approval.

Scientific evidence and supplier documentation answer different questions

A receptor study asks how a defined test article interacts with a biological system. An animal study asks what happened in a particular model. A human study reports outcomes in enrolled participants under a protocol. None of those records determines what is inside a current supplier vial.

Supplier documentation can support claims about a named sample when the product, lot, sample identifier, laboratory, method, date, expected result, and observed result form a coherent chain. It cannot turn an exploratory finding into established efficacy, prove long-term safety, or make an unapproved substance approved.

Research use only is an intended-use statement, not an analytical result. It does not mean pharmaceutical grade, sterile, endotoxin controlled, clinically equivalent, safe, effective, or independently authenticated.

Analytical questions for Melanotan II research material

Identity review should begin with the complete represented structure: acetylated N-terminus, norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan, lysine, the specified lactam ring closure, and the C-terminal amide. A linear peptide, an L-phenylalanine substitution, or a different ring connection is not the same molecule.

Mass spectrometry can support expected molecular mass when charge states, adducts, calibration, sample, and lot are interpretable. Chromatography can separate detected components under the stated method. Neither test alone proves the full sequence, stereochemistry, ring topology, absolute peptide content, water, counterion amount, residual solvents, sterility, endotoxin, stability, or biological equivalence.

A useful documentation record also distinguishes HPLC area purity from net peptide quantity. The mass printed on a vial can include peptide, counterion, water, and other components unless the quantitative basis is clearly defined and supported.

• Complete sequence and acetylated N-terminus
• Norleucine and D-phenylalanine identity
• Specified lactam bridge and C-terminal amide
• Expected mass and stated salt or counterion form
• Lot-matched identity and chromatographic purity reported separately
• Peptide content, water, counterion, and residual-solvent evidence where claimed
• Separate sterility and endotoxin evidence for any microbiological claim
• No inference of clinical equivalence from a familiar name or purity percentage

Limitations and unresolved questions

The receptor literature needs continued work on subtype selectivity, signaling bias, tissue-specific exposure, and how individual receptor pathways combine in whole-organism effects. A compound that reaches several receptors can produce intertwined effects that simple labels obscure.

The human literature is too small to establish a clinical role. Larger prospectively registered studies would need transparent endpoints, diverse participants, adequate follow-up, complete adverse-event reporting, and independent replication before confident benefit-risk conclusions could be drawn.

The online supply chain adds a separate uncertainty layer. Public records may leave structure, stereochemistry, ring closure, net peptide content, impurities, aggregation, microbiological quality, and stability unresolved. Biological literature cannot repair those analytical gaps.

FAQ: Is Melanotan II the same as Melanotan I or afamelanotide?

No. Melanotan II is a cyclic analog, while afamelanotide is a different, linear alpha-MSH analog associated with the earlier Melanotan I name. Scenesse approval is specific to an afamelanotide finished drug product and does not apply to MT-II.

FAQ: Is Melanotan II the same as bremelanotide or PT-141?

No. Bremelanotide was developed from the Melanotan II lineage but has a different chemical identity. Evidence and FDA labeling for the bremelanotide product Vyleesi cannot be transferred to MT-II.

FAQ: Is Melanotan II FDA approved?

No FDA-approved Melanotan II drug product was identified as of October 28, 2026. A substance-registration identifier, withdrawn compounding nomination, research-use label, or planned advisory-committee discussion does not constitute approval.

FAQ: Does 99% HPLC purity prove a sample is Melanotan II?

No. An HPLC area percentage describes detected chromatographic components under one method. It does not by itself establish sequence, D-phenylalanine, cyclization, terminal chemistry, absolute peptide content, counterion, water, residual impurities, sterility, endotoxin, stability, or equivalence to a study material.

The defensible conclusion

Melanotan II is a useful research tool for studying melanocortin biology, but its human evidence remains exceptionally limited. Receptor and animal studies support several mechanistic hypotheses; three tiny human experiments reported pigmentation or erectile-response signals together with adverse effects. That record is not a confirmed clinical evidence base.

Reliable due diligence keeps six questions separate: exact molecular identity, receptor pharmacology, animal-model findings, human outcomes, product-specific regulatory status, and lot-specific supplier documentation. Collapsing them into one claim creates certainty that the evidence does not support.